Centivax is a private company building in biotechnology - vaccines, founded in 2017. Its shares do not trade on a public exchange.
Centivax has no published valuation.
Centivax is a broad-spectrum immunity company developing vaccines and antibodies using computational immunology, based in South San Francisco, California. Founder Jacob Glanville founded Centivax Inc and spun out his assets in COVID-19 therapeutics, broad-spectrum vaccines, and antivenom antibodies into the company.
Its lead candidate, Centi-Flu 01, is designed to focus immune responses on conserved regions of the influenza virus shared across strains, aiming for durable protection against both seasonal and pandemic flu without annual reformulation. By early 2026 the vaccine's Phase 1 trial had nearly all 180 participants enrolled.
Listed funds carry late-stage private names. A fund's latest schedule of investments shows whether it holds Centivax.
Often trade at a premium or discount to NAV.
Platforms match existing holders with buyers. Centivax availability at any moment is set by the holders.
High minimums, transfer approval, company right-of-first-refusal.
Valuations, rounds and IPO status for every company in the directory — Centivax included.
No. Centivax is a private company; its shares do not trade on a public exchange.
Lead investors for each round are in the funding timeline.
The closest biotechnology - vaccines peers are on the competitors page.
The routes section explains what is realistically available for a company at this stage.
Perpetual markets for stocks, gold, indices and pre-IPO names — settled on-chain, no wallet-to-exchange transfers.
